Brevan Howard Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Brevan Howard Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$180K	Buy	+18,888	New	+$147K	﹤0.01%	1926
2025 Q4	–	Sell	-325,795	Closed	-$2.47M	–	1807
2025 Q3	$2.47M	Buy	325,795 +187,491	+136%	+$1.56M	0.04%	467
2025 Q2	$1.24M	Buy	138,304 +84,282	+156%	+$785K	0.01%	962
2025 Q1	$405K	Sell	54,022 -2,622	-5%	-$21.1K	0.01%	774
2024 Q4	$426K	Sell	56,644 -22,824	-29%	-$173K	0.01%	664
2024 Q3	$604K	Sell	79,468 -14,999	-16%	-$114K	0.03%	631
2024 Q2	$584K	Buy	94,467 +81,968	+656%	+$452K	0.04%	553
2024 Q1	$63.5K	Sell	12,499 -57,592	-82%	-$324K	0.01%	928
2023 Q4	$420K	Buy	+70,091	New	+$406K	0.04%	564

Other funds holding BCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return